Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

PRINCETON, N.J., March 19, 2015-- Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in a Phase 1/ 2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV, an investigational Lm- LLO immunotherapy, for the treatment of patients with recurrent cervical cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.